Therapeutics and Research in Oncology (TRIO) Registers with OneOncology
News Feb 05, 2008
OneOncology Inc. has announced that Therapeutics and Research in Oncology (TRIO) and its 50 plus member-practices in Maryland, Virginia and Washington, D.C. have registered with OneOncology to use its electronic negotiation platform to simplify oncology drug purchasing.
TRIO joins more than 175 practices representing more than 650 physicians and $1.6 billion in annual purchasing already registered with OneOncology.
“We are honored to welcome TRIO and all its members to OneOncology,” said Steven Kirchof, CEO of OneOncology. “We look forward to working with TRIO in pursuit of our shared goal of uniting the oncology community to create a transparent, open market for oncology drug purchasing.”
OneOncology is an impartial electronic trading hub that aggregates individual drug orders from oncology practices across the country and allows drug distributors to bid to fill those orders at competitive prices.
The technology can provide complete transparency for the drug purchasing process, allow qualified U.S. distributors to participate in the growing oncology arena and enable oncologists to build healthier practices. OneOncology is uniting the oncology market to ensure community cancer care survives.
“OneOncology can help us secure more competitive pricing on oncology drugs while simplifying our drug purchasing process so that we can stay focused on our primary passion for patient care,” said TRIO Secretary Treasurer Ram Trehan, MD. “We hope all of the state societies, physicians, distributors and manufacturers across the country will join together with us to increase competition and transparency that will lower prices in the oncology market.”
“The issue of transparency in areas such as the wide variability of drug prices is significant concern. For example, among current practices that have registered with OneOncology, we have seen that there is a $98 difference between the lowest and highest off-invoice price paid for the exact same vial of drug. Even more surprising is the fact that the lowest price for many drugs is not always associated with the largest volume purchasers,” Kirchof said.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE